Rachel Sigsworth
University of Leeds(GB)Cancer Research UK Clinical Trials Unit(GB)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Cancer Treatment and Pharmacology, Cancer therapeutics and mechanisms, Ethics in Clinical Research, Meta-analysis and systematic reviews
Most-Cited Works
- → Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial(2016)76 cited
- → Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial(2023)15 cited
- → Clinical trial recruiters’ experiences working with trial eligibility criteria: results of an exploratory, cross-sectional, online survey in the UK(2021)13 cited
- → Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial(2022)8 cited
- → Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance(2019)4 cited
- → Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); A Report of Second Primary Malignancy (SPM) Rates and the Importance of Review of Reported Cases(2015)2 cited
- → Guidelines for the correct determination of second primary malignancies in myeloma trials(2015)1 cited
- → Clinical Trial Recruiters’ Experiences Working With Trial Eligibility Criteria: Results of an Exploratory, Cross-sectional, Online Survey(2021)1 cited
- → Correction to: Clinical trial recruiters’ experiences working with trial eligibility criteria: results of an exploratory, cross-sectional, online survey in the UK(2021)1 cited
- → The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial(2023)